Apimeds Pharmaceuticals US Inc

Research Apimeds Pharmaceuticals US Inc (APUS) on Bullrun: market cap USD 75.00M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 75.00M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 6.00M-USD 8.98Mn/a-0.55USD 1.64MUSD 7.76MUSD 153.35M
FY2024USD 0-USD 1.39M-USD 733.53Kn/a-0.18USD 3.46KUSD 596.84K-USD 1.36M
FY2023n/a-USD 777.69Kn/an/a-0.17USD 410.48Kn/aUSD 31.87K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 75.00Mn/an/an/a
20252025-12-31USD 206.25Mn/an/an/a

About Apimeds Pharmaceuticals US Inc

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Apimeds Pharmaceuticals US Inc's market cap?

Apimeds Pharmaceuticals US Inc's market capitalization is USD 75.00M.

What does Apimeds Pharmaceuticals US Inc do?

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.